公开(公告)号：US20160324834A1

公开(公告)日：2016-11-10

申请号：US15156207

申请日：2016-05-16

Applicant: Emory University

Inventor： Rafi R. Ahmed ,  Christian P. Larsen ,  Koichi Araki

IPC: A61K31/436 ,  A61K39/00

CPC classification number: A61K31/436 ,  A61K31/4745 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K14/005 ,  C12N2710/10343 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2730/10134 ,  C12N2740/13023 ,  C12N2740/13043 ,  C12N2760/10034 ,  C12N2770/10022 ,  A61K2300/00

Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.

Abstract translation: 本文公开了用mTOR抑制剂治疗受试者增强抗原特异性T细胞免疫应答。 因此，本文提供了通过向受试者施用治疗有效量的mTOR抑制剂来增强受试者中抗原特异性T细胞应答的方法。 抗原可以是任何抗原，例如来自病原体或疫苗的抗原或肿瘤抗原。 在一些实施方案中，该方法还包括向受试者施用疫苗，例如病毒疫苗或癌症疫苗。 mTOR抑制剂可以在接种之前或之后施用以增强T细胞免疫应答和免疫记忆的数量和质量。 在一些实例中，mTOR抑制剂是雷帕霉素或雷帕霉素类似物。

公开(公告)号：US09441015B2

公开(公告)日：2016-09-13

申请号：US14667697

申请日：2015-03-25

Applicant: NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Mei-Li Wu ,  Hso-Chi Chaung ,  Guan-Ming Ke

IPC: C07K14/005 ,  C12N7/00 ,  A61K39/39 ,  A61K39/12 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/55561 ,  A61K2039/70 ,  C07K2319/00 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10071 ,  C12N2799/026

Abstract: The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (PRRSV). A recombinant fusion antigen gene, which encodes glycoprotein GP5 with truncated N′-terminal decoy epitope, a linker sequence and membrane protein M, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein. The recombinant fusion antigen protein can be applied in a subunit vaccine composition, for providing vaccinated animals with better protection ability without the risks of virulent spread and virulent recovery.

Abstract translation: 本发明涉及重组融合抗原基因，重组融合抗原蛋白和与猪繁殖与呼吸综合征病毒（PRRSV）感染相同的亚单位疫苗组合物。 编码具有截短的N末端诱饵表位的糖蛋白GP5，接头序列和膜蛋白M，然后密码子优化的重组融合抗原基因在体外由杆状病毒表达系统表达，从而提高重组融合物的产量 抗原蛋白。 重组融合抗原蛋白可以应用于亚单位疫苗组合物中，为疫苗接种的动物提供更好的保护能力，而不会产生毒性扩散和毒性恢复的风险。

公开(公告)号：US09315781B2

公开(公告)日：2016-04-19

申请号：US14235596

申请日：2012-07-30

Applicant: Christiane Fetzer ,  Andreas Gallei

Inventor： Christiane Fetzer ,  Andreas Gallei

IPC: C12N7/00 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N2770/10021 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10062

Abstract: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone useful for studying Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS.

Abstract translation: 本发明属于动物健康领域，涉及一种核酸序列，其包含可用于研究猪繁殖与呼吸综合征（PRRS）的感染性基因型I（EU）PRRS病毒克隆的基因组，其是影响猪的病毒性疾病， 以及开发用于预防，治疗和诊断PRRS的疫苗，治疗和诊断。

公开(公告)号：US20140314808A1

公开(公告)日：2014-10-23

申请号：US14235596

申请日：2012-07-30

Applicant: Christiane Fetzer ,  Andreas Gallie

Inventor： Christiane Fetzer ,  Andreas Gallie

IPC: C12N7/00

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N2770/10021 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10062

Abstract: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone useful for studying Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS.

Abstract translation: 本发明属于动物健康领域，涉及一种核酸序列，其包含可用于研究猪繁殖与呼吸综合征（PRRS）的感染性基因型I（EU）PRRS病毒克隆的基因组，其是影响猪的病毒性疾病， 以及开发用于预防，治疗和诊断PRRS的疫苗，治疗和诊断。

公开(公告)号：US08709730B2

公开(公告)日：2014-04-29

申请号：US12594774

申请日：2008-04-07

Applicant: Adolfo Garcia-Sastre ,  Natalia Frias-Staheli ,  Herbert W. Virgin ,  Nadia Vicki Giannakopoulos

Inventor： Adolfo Garcia-Sastre ,  Natalia Frias-Staheli ,  Herbert W. Virgin ,  Nadia Vicki Giannakopoulos

IPC: G01N33/53 ,  A61K39/12

CPC classification number: C07K14/005 ,  C12N7/00 ,  C12N2760/12021 ,  C12N2760/12022 ,  C12N2770/10022

Abstract: Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and/or deubiquitinate ubiquitinated proteins and/or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and/or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and/or deubiquitination and/or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and/or management of viral infections.

Abstract translation: 具有减弱ISG15缀合物脱敏能力的病毒，特别是包含病毒基因组中的突变的病毒突变体，其降低或消除由病毒基因组编码的病毒OTU结构域的蛋白质使ISG15缀合物和/或泛素化泛素化的能力脱落 公开了蛋白质和/或脱硝化二烯酸化蛋白质。 这样的病毒突变体可用于诱导免疫应答和预防，控制和/或治疗病毒感染的免疫原性组合物的制剂中。 还公开了用于鉴定抗病毒化合物的方法，特别是鉴定降低或抑制含有病毒OTU结构域的蛋白质的脱甲硅烷基化活性和/或去泛素化和/或脱亚氨基化活性的化合物的方法。 使用这些方法鉴定的化合物可用作预防，治疗和/或管理病毒感染的抗病毒剂。

公开(公告)号：US08492132B2

公开(公告)日：2013-07-23

申请号：US12607358

申请日：2009-10-28

Applicant: Jay G. Calvert ,  Michael G. Shepard ,  Siao-Kun W. Welch

Inventor： Jay G. Calvert ,  Michael G. Shepard ,  Siao-Kun W. Welch

IPC: C12N7/01 ,  C07H21/04 ,  C12N15/63

CPC classification number: C07K14/005 ,  A61K2039/525 ,  A61K2039/53 ,  C12N15/86 ,  C12N2770/10022 ,  C12N2770/10043

Abstract: The invention provides isolated polynucleotide molecules, plasmids, viral vectors, and transfected host cells that comprise a DNA molecule encoding an infectious RNA molecule that encode a PRRS (Porcine Reproductive and Respiratory Syndrome) virus, and further provides the PRRS virus encoded thereby. The invention also provides isolated infectious RNA molecules encoding PRRS virus.

Abstract translation: 本发明提供分离的多核苷酸分子，质粒，病毒载体和转染的宿主细胞，其包含编码编码PRRS（猪繁殖和呼吸综合征）病毒的感染性RNA分子的DNA分子，并进一步提供由其编码的PRRS病毒。 本发明还提供编码PRRS病毒的分离的感染性RNA分子。

公开(公告)号：US20130028931A1

公开(公告)日：2013-01-31

申请号：US13558669

申请日：2012-07-26

Applicant: Andreas GALLEI

Inventor： Andreas GALLEI

IPC: C12N7/00 ,  C12N7/04 ,  C12N15/40 ,  C12N15/85 ,  C12Q1/70 ,  A61P31/14 ,  G01N21/55 ,  G01N21/64 ,  G01N21/78 ,  G01N21/75 ,  A61K39/12 ,  A61P37/04 ,  C12N7/01 ,  C12N5/10

CPC classification number: C12N7/00 ,  A61K35/76 ,  A61K39/12 ,  A61K2039/552 ,  C07K14/005 ,  C12N2770/10021 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10062

Abstract: The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus.

Abstract translation: 本发明涉及可用作预防或治疗猪繁殖和呼吸综合征（PRRS）的疫苗或药物的减毒活病毒领域，并且基于能够诱导干扰素型的PRRS病毒的惊人发现 我对所述病毒感染的细胞的反应。 在一个实施方案中，根据本发明的PRRS病毒是PRRS病毒突变体，其与野生型菌株的基因组相比，包含编码所述病毒的非结构蛋白1（nsp1）的基因中的突变。

公开(公告)号：US20110104201A1

公开(公告)日：2011-05-05

申请号：US12389558

申请日：2009-02-20

Applicant: William L. Mengeling ,  Ann Vorwald ,  Kelly Lager ,  Mike Roof ,  Kelly Burkhart ,  David E. Gorcyca

Inventor： William L. Mengeling ,  Ann Vorwald ,  Kelly Lager ,  Mike Roof ,  Kelly Burkhart ,  David E. Gorcyca

IPC: A61K39/12 ,  C07H21/04 ,  C12N7/00 ,  A61P37/02 ,  A61P31/12

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N7/00 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10061 ,  C12N2770/10064 ,  Y10S424/815

Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

Abstract translation: 提供基本上无毒的形式的非典型猪繁殖与呼吸综合征（PRRS）病毒和相应的疫苗，其由PRRS的毒性形式的细胞培养传代产生。 所得到的无毒非典型PRRS病毒可用作疫苗，因为通过接种宿主动物引起PRRS特异性抗体应答，从而赋予先前已知的PRRS病毒株和新分离的非典型PRRS病毒株的有效免疫。 优选的传代技术确保病毒在整个过程中基本上保持在对数生长阶段，这使得实现衰减所需的时间最小化。 本发明还提供可区分感染野外毒株的动物和PRRSV减毒菌株的诊断测试方法。

公开(公告)号：US20110040079A1

公开(公告)日：2011-02-17

申请号：US12615504

申请日：2009-11-10

Applicant: JAY GREGORY CALVERT ,  MICHAEL G. SHEPPARD ,  SIAO-KUN W. WELCH ,  RAYMOND R.R. ROWLAND ,  DAL-YOUNG KIM

Inventor： JAY GREGORY CALVERT ,  MICHAEL G. SHEPPARD ,  SIAO-KUN W. WELCH ,  RAYMOND R.R. ROWLAND ,  DAL-YOUNG KIM

IPC: C07H21/04

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/55577 ,  C07K2319/42 ,  C07K2319/60 ,  C12N7/00 ,  C12N15/86 ,  C12N2770/10021 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10043 ,  C12N2770/10061 ,  G01N33/56983 ,  G01N2333/08

Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.

Abstract translation: 本发明提供了分离的多核苷酸分子，其包含编码编码经遗传修饰的北美PRRS病毒的感染性RNA序列的DNA序列，其中多核苷酸分子缺少至少一种可检测的北美PRRS病毒抗原表位。 本发明还提供包含经遗传修饰的北美PRRS病毒，RNA分子，质粒和包含分离的多核苷酸分子的病毒载体的疫苗。 还提供了进一步包含编码可检测的异源抗原表位的至少一个核苷酸序列的分离的多核苷酸分子，以及包含北美PRRS病毒，RNA分子，质粒和包含这种分离的多核苷酸分子的病毒载体的疫苗。

公开(公告)号：US20100035276A1

公开(公告)日：2010-02-11

申请号：US12576067

申请日：2009-10-08

Applicant: Michael P. Murtaugh ,  Craig R. Johnson

Inventor： Michael P. Murtaugh ,  Craig R. Johnson

IPC: G01N33/53

CPC classification number: G01N33/56983 ,  C07K14/005 ,  C12N2770/10022 ,  G01N2333/08 ,  G01N2469/20

Abstract: This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS virus antibodies. In other embodiments, this document provides methods and materials that can be used to determine if a particular organism received a vaccine version of a virus, was infected with a naturally-occurring version of the virus, or is naive with respect to the virus.

Abstract translation: 本文件提供了与有机体相关的方法和材料，用于存在或不存在抗病毒抗体。 例如，本文件提供了可用于确定生物（例如猪品种如猪的成员）是否含有抗PRRS病毒抗体的方法和材料。 在其他实施方案中，本文件提供了可用于确定特定生物体是否接收到病毒的疫苗版本的方法和材料，被感染了天然存在的病毒版本，或者相对于病毒是天真的。